Development
Lantern Pharma Inc.
LTRN
$3.32
-$0.11-3.21%
NASDAQ
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Net Income | -5.12% | 12.02% | 0.19% | -15.34% | -23.04% |
| Total Depreciation and Amortization | 55.01% | 55.95% | 56.10% | 55.78% | 1,586.21% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -39.24% | -12.38% | 30.60% | 81.73% | 31.82% |
| Change in Net Operating Assets | 362.42% | -204.21% | -239.03% | -201.98% | 80.21% |
| Cash from Operations | -12.30% | -9.97% | -12.08% | -20.54% | -19.93% |
| Capital Expenditure | 0.96% | -27.68% | -137.42% | -80.00% | -1.95% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 11.60% | 44.70% | 95.23% | 101.06% | 96.70% |
| Cash from Investing | 11.27% | 43.90% | 95.05% | 100.92% | 96.59% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | -100.00% | -100.00% | -99.57% | -99.47% |
| Repurchase of Common Stock | 100.00% | 100.00% | 100.00% | -164.16% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 100.00% |
| Cash from Financing | 100.00% | 100.00% | 100.00% | -103.44% | -104.75% |
| Foreign Exchange rate Adjustments | 29.38% | 122.59% | -626.47% | -1,063.64% | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 10.35% | 14.39% | 58.54% | -144.39% | -145.52% |